DVT Diagnosis and Treatment: What to Expect in the ER or Clinic

Deep vein thrombosis (DVT) evaluation follows a structured pathway to confirm diagnosis, assess severity, and initiate appropriate anticoagulation.

1. Initial Clinical Assessment

• History: Symptom onset, location, character, progression; risk factors (surgery, immobilization, cancer, hormones, travel, prior VTE, thrombophilia).
• Review medications, allergies, bleeding history.

2. Physical Examination

• Inspect and palpate both legs: swelling, erythema, warmth, tenderness, collateral veins.
• Measure calf and thigh circumference (10 cm below tibial tuberosity; >2 cm difference significant).
• Homan's sign (calf pain on dorsiflexion) insensitive and nonspecific—do not rely on it.
• Vital signs: tachycardia, hypotension may suggest PE.

3. Pre-Test Probability: Wells Score

Stratifies patients to guide testing:

• Low probability (≤0): D-dimer first.
• Moderate/high (≥1): Proceed directly to imaging.

4. Diagnostic Testing

D-dimer

• High sensitivity, low specificity. Negative in low-probability patients effectively rules out DVT.
• Elevated in pregnancy, inflammation, malignancy, elderly, post-op—limited utility there.

Imaging (Gold Standard)

• Duplex ultrasound (compression + Doppler): First-line. Non-invasive, no radiation. Sensitivity >95% for proximal DVT; lower for calf/distal.
• CT venography / MR venography: If ultrasound equivocal or iliac/caval/IVC thrombus suspected.
• Contrast venography: Historical gold standard; rarely used now (invasive).

5. Blood Work (Baseline)

• CBC, renal function (CrCl for DOAC dosing), liver function, coagulation studies (PT/INR, aPTT), baseline hemoglobin.
• Thrombophilia workup: Not acute; consider later if unprovoked, young, recurrent, or family history.

6. Treatment Initiation

• Anticoagulation (immediate): DOAC preferred (apixaban, rivaroxaban, edoxaban, dabigatran) — no monitoring, fixed dosing, lower intracranial bleed risk. VKA (warfarin) if mechanical valve, APS, severe renal impairment, or cost barrier.
• Parenteral bridge: LMWH/UFH if DOAC not feasible or for massive iliofemoral DVT with thrombolysis consideration.
• Thrombolysis (CDT/systemic): Selected iliofemoral DVT <14 days, low bleed risk, good functional status—preserves valve function, reduces PTS.
• IVC filter: Only if anticoagulation contraindicated and high PE risk.
• Compression stockings: 20–30 mmHg for symptomatic relief; unclear for PTS prevention.

7. Follow-Up

• 1–2 weeks: Assess compliance, bleeding, renal function.
• 3 months: Decide duration (3 months provoked; indefinite if unprovoked/recurrent/cancer).
• Monitor for post-thrombotic syndrome (Villalta scale).

Prompt evaluation saves lives. If DVT suspected, seek care immediately.